Drug intelligence / Profile preview

EMPA-GUARD

Development stage: Unknown
Lead developer: JW Theriac Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

**EMPA-GUARD** is a small-molecule fixed-dose combination being developed by JW Theriac Pharmaceuticals, with SKK identified as a partner in the provided context, for the treatment of **type 2 diabetes mellitus**. It is described as a dual-mechanism antihyperglycemic therapy that combines **DPP-4 inhibition** and **SGLT2 inhibition** in a single formulation to improve glycemic control. Based on the supplied development context, the program has completed Phase 3 testing and is under **NDA review** as a modified new drug.

Brand names: EMPA-GUARD

Targets

SGLT2 (Sodium-glucose cotransporter protein subunit 2)

Beyond the preview

Go deeper on EMPA-GUARD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EMPA-GUARD.

Explore the full profile